Over 4 million people live with diabetes in the UK, and Type 1 diabetes (T1D) accounts for about 10% of that population.1 Continuous subcutaneous insulin infusion (CSII), insulin pump therapy, is a technological advancement used to support people with T1D manage their diabetes optimally. The gene discussed is INS; the disease is type 1 diabetes mellitus.